BIM-23190
BIM-23190, a somatostatin analog, a selective SSTR2 and SSTR5 agonist, exhibits Ki values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly[1][3].
Product Specifications
CAS Number
182153-96-4
UNSPSC
12352209
Target
Somatostatin Receptor
Type
Peptides
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bim-23190.html
Solubility
10 mM in DMSO
Smiles
O=C(N[C@H](C(N[C@H](C(N1)=O)CC)=O)CCCCN)[C@H](NC([C@@H](NC([C@H](CSSC[C@H]1C(N[C@H](C(N)=O)[C@H](O)C)=O)NC([C@H](NC(CN(CC2)CCN2CCO)=O)CC3=CC=CC=C3)=O)=O)CC(C=C4)=CC=C4O)=O)CC5=CNC6=CC=CC=C56
Molecular Formula
C57H79N13O12S2
Molecular Weight
1202.45
References & Citations
[1]I Shimon, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997 Nov 1;100 (9) :2386-92.|[2]Federica Barbieri, et al. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am J Physiol Endocrinol Metab. 2009 Nov;297 (5) :E1078-88.|[3]T J Gillespie, et al. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther. 1998 Apr;285 (1) :95-104.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
SSTR2; SSTR5
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
